Truist Financial’s Supernus Pharmaceuticals SUPN Stock Holding History

Truist Financial’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-21,866	Closed	-$657K	–	2671
2023 Q2	$657K	Sell	21,866 -3,302	-13%	-$116K	﹤0.01%	1812
2023 Q1	$912K	Sell	25,168 -322	-1%	-$12.4K	﹤0.01%	1604
2022 Q4	$909K	Buy	25,490 +16,499	+184%	+$573K	﹤0.01%	1597
2022 Q3	$304K	Sell	8,991 -8,909	-50%	-$290K	﹤0.01%	2085
2022 Q2	$517K	Sell	17,900 -376	-2%	-$10.8K	﹤0.01%	1880
2022 Q1	$590K	Sell	18,276 -814	-4%	-$25K	﹤0.01%	1909
2021 Q4	$557K	Buy	19,090 +771	+4%	+$23.4K	﹤0.01%	1949
2021 Q3	$489K	Buy	+18,319	New	+$492K	﹤0.01%	2019
2020 Q3	–	Sell	-13,845	Closed	-$329K	–	2557
2020 Q2	$329K	Buy	13,845 +172	+1%	+$3.8K	﹤0.01%	1885
2020 Q1	$246K	Buy	+13,673	New	+$287K	﹤0.01%	1986

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Truist Financial's SUPN Position: Q3 2023 in Review

Truist Financial sold out of Supernus Pharmaceuticals (SUPN) in Q3 2023, closing a stake of 21,866 shares — an estimated $657K sold.

Truist Financial first reported a position in SUPN in Q1 2020 and held it in 10 quarters. The position peaked at $912K in Q1 2023. 238 funds tracked by Wall St. Rank hold SUPN as of Q3 2023.

Truist Financial reported no remaining Supernus Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
Truist Financial sold 21,866 Supernus Pharmaceuticals shares in Q3 2023, an estimated $657K.
Truist Financial first reported a position in Supernus Pharmaceuticals in Q1 2020 and held it in 10 quarters.
Truist Financial's Supernus Pharmaceuticals position peaked at $912K in Q1 2023.
238 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2023.

Based on Truist Financial's 13F filing for Q3 2023, filed 14 Nov 2023.